All Title Author
Keywords Abstract

PLOS Medicine  2004 

Is It Ethical to Use Enhancement Technologies to Make Us Better than Well?

DOI: 10.1371/journal.pmed.0010052

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background to the Debate A variety of biomedical technologies are being developed that can be used for purposes other than treating disease. Such “enhancement technologies” can be used to improve our appearance and regulate our emotions, with the goal of feeling “better than well.” While these technologies can help people adapt to their rapidly changing lifestyles, their use raises important ethical issues.

References

[1]  President's Council on Bioethics (2003) Beyond therapy: Biotechnology and the pursuit of happiness. New York: Dana Press. 400 p.
[2]  McKibben W (2003) Enough: Staying human in an engineered age. New York: Times Books. 271 p.
[3]  Callahan D (2003) What price better health? Hazards of the research imperative. Berkeley: University of California Press. 329 p.
[4]  Elliott C (2003) Better than well: American medicine meets the American dream. New York: W. W. Norton. 357 p.
[5]  Fukuyama F (2003) Our posthuman future: Consequences of the biotechnology revolution. New York: Picador. 272 p.
[6]  Rothman S, Rothman D (2003) The pursuit of perfection: The promise and perils of medical enhancement. New York: Pantheon Books. 292 p.
[7]  Kass LR (2002) Life, liberty, and the defense of dignity: The challenge for bioethics. San Francisco: Encounter Books. 313 p.
[8]  Kristol W, Cohen E (2002) The future is now: America confronts the new genetics. Lanham (Maryland): Rowman and Littlefield. 357 p. editors.
[9]  Sandel S2004 The case against perfection. Atlantic Monthly April51–62.
[10]  Isaacson W (2003) Benjamin Franklin: An American life. New York: Simon and Schuster. 590 p.
[11]  Whorton J (1984) Crusaders for fitness: The history of American health reformers. Princeton (New Jersey): Princeton University Press. 359 p.
[12]  Caplan AL (2004) Is biomedical research too dangerous to pursue? Science 303: 1142.
[13]  Saint Teresa of Avila (1964) The way of perfection. Garden City, New York: Image Books. 320 p. In Peers EA, translator. Available: www.ccel.org/t/teresa/way/main.html. Accessed 16 October 2004.
[14]  Pinker S (2002) The blank slate: The modern denial of human nature. New York: Viking. 509 p.
[15]  Tenner E (2003) Our own devices: The past and future of body technology. New York: Alfred A. Knopf. 314 p.
[16]  Moynihan R (2002) Drug firms hype disease as sales ploy, industry chief claims. BMJ 324: 867.
[17]  Mundy A (2001) Dispensing with the truth: The victims, the drug companies, and the dramatic story behind the battle over Fen-Phen. New York: St. Martin's Press. 402 p.
[18]  Barrett A2004 Wyeth: The class action that wouldn't quit. Business Week 52488.
[19]  Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321–333.
[20]  Whittington C, Kendall T, Fonagy P, Cottrell D, Cotgrove A, et al. (2004) Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363: 1341–1344.
[21]  Kassirer J (2004) On the take: How medicine's complicity with big business can endanger your health. New York: Oxford University Press. 251 p.
[22]  Moynihan R, Heath I, Henry D (2002) Selling sickness: The pharmaceutical industry and disease mongering. BMJ 324: 886–891.
[23]  Greider K (2003) The big fix: How the pharmaceutical industry rips off American consumers. New York: Public Affairs. 189 p.
[24]  Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. New York: Random House. 305 p.
[25]  Elliott C (2004) Pharma buys a conscience. Am Prospect 12(17): 16–20.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal